Bevacizumab for glioma and radiation encephalic necrosis

Abstract

Pan Xuefeng, Xing Hongyu, Zheng Guobao. Bevacizumab for glioma and radiation encephalic necrosis[J]. Journal of International Oncology, 2014, 41(1): 27-30.

［1］ Kerbel RS. Tumor angiogenesis［J］. New Engl J Med, 2008, 358(19):20392049. ［2］ Vaziri SA, Kim J, Ganapathi MK, et al. Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors［J］. Curr Oncol Rep, 2010, 12(2):102108. ［3］ Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5year analysis of the EORTCNCIC trial［J］. Lancet Oncol, 2009, 10(5):459466. ［4］ Pichler J, Marosi C. Drug therapy of patients with recurrent glioblastoma: is there any evidence?［J］. Wien Med Wochenschr, 2011, 161(12):2631. ［5］ Onishi M, Ichikawa T, Kurozumi K, et al. Angiogenesis and invasion in glioma［J］. Brain Tumor Pathol, 2011, 28(1):1324. ［6］ Maiuri F, Del Basso De Caro M, Siciliano A, et al. Expression of growth factors in brain tumors: correlation with tumor grade,recurrence and survival［J］. Clin Neuropathol, 2010, 29(2):109114. ［7］ Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme［J］. J Clin Oncol, 2007, 25(30):47224729. ［8］ Desjardins A, Reardon DA, Herndon JE 2nd. et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas［J］. Clin Cancer Res, 2008, 14(21):70687073. ［9］ Kreisl TN, Kim L, Moore K, et al. Phase Ⅱ trial of singleagent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma［J］. J Clin Oncol, 2009, 27(5):740745. ［10］ Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma［J］. J Clin Oncol, 2009, 27(28):47334740. ［11］ Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma［J］. Cancer, 2012, 118(5):13021312. ［12］ Reardon DA, Desjardins A, Peters KB, et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy［J］. Cancer, 2011, 117(23):53515358. ［13］ Cuneo KC, Vredenburgh JJ, Sampson JH, et al. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas［J］. Int J Radiat Oncol Biol Phys, 2012, 82(5):20182024. ［14］ Taal W, Oosterkamp HM, Walenkamp A ME, et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study［J］. J Clin Oncol, 2013, 31 Suppl:2001. ［15］ Lai A, Tran A, Nghiemphu PL, et al. Phase Ⅱ study of bevaeizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme［J］. J Clin Oncol, 2011, 29(2):142148. ［16］ Gilbert MR, Dignam J, Won M, et al. RTOG 0825: Phase Ⅲ doubleblind placebocontrolled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM)［J］. J Clin Oncol, 2013, 31 Suppl:1. ［17］ Henriksson R, Bottomley A, Mason W, et al. Progressionfree survival (PFS) and healthrelated quality of life (HRQoL) in AVAglio, a phase Ⅲ study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM)［J］. J Clin Oncol, 2013, 31 Suppl:2005. ［18］ Herrlinger U, Schaefer N, Steinbach JP, et al. Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMTnonmethylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial［J］. J Clin Oncol, 2013, 31 Suppl:LBA2000. ［19］ Fink J, Born D, Chamberlain MC. Radiation necrosis: relevance with respect to treatment of primary and secondary brain tumors［J］. Curr Neurol Neurosci Rep, 2012, 12(3):276285. ［20］ Siu A, Wind JJ, Iorgulescu JB, et al. Radiation necrosis following treatment of high grade gliomaa review of the literature and current understanding［J］. Acta Neurochir(Wien), 2012, 154(2):191201. ［21］ Gonzalez J, Kumar AJ, Conrad CA, et al. Effect of bevacizumab on radiation necrosis of the brain［J］. Int J Radiat Oncol Biol Phys, 2007, 67(2):323326. ［22］ Wong ET, Huberman M, Lu XQ, et al. Bevacizumab reverses cerebral radiation necrosis［J］. J Clin Oncol, 2008, 26(34):56495650. ［23］ Liu AK, Macy ME, Foreman NK, et al. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas［J］. Int J Radiat Oncol Biol Phys, 2009, 75(4):11481154. ［24］ Benoit A, Ducray F, CartalatCarel S, et al. Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis［J］. J Neurol, 2011, 258(2):328329. ［25］ Levin VA, Bidaut L, Hou P, et al. Randomized doubleblind placebocontrolled trial of bevacizumab therapy for radiation necrosis of the central nervous system［J］. Int J Radiat Oncol Biol Phys, 2011, 79(5):14871495. ［26］ Keunen O, Johansson M, Oudin A, et al. AntiVEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma［J］. Proc Natl Acad Sci USA, 201l, 108(9):37493754. ［27］ de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab:radiographic and pathologic correlation in humans and mice［J］. Neuro Oncol, 2010, 12(3):233242. ［28］ Furuse M, Kawabata S, Kuroiwa T, et al. Repeated treatment with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases［J］. J Neurooncol, 2011, 102(3):471475.

[1]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197.
[2]	Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun.Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases[J]. Journal of International Oncology, 2023, 50(3): 138-143.
[3]	Fei Wenjing, Wang Wenbao, Xie Huanhuan, Yan Jing, Yang Mi.Research status of glioblastoma-associated microglia[J]. Journal of International Oncology, 2022, 49(7): 420-424.
[4]	Xiao Nan, Sun Pengfei.Research progress of oxidative stress in the sensitivity of chemoradiotherapy for gliomas[J]. Journal of International Oncology, 2022, 49(6): 357-361.
[5]	Sun Xiaolin, Zhang Zhanyu, Xu Linzong, Liu Yingchao, Li Xiaomei.Potential value of radiotherapy combined with immunotherapy in breast cancer brain metastases[J]. Journal of International Oncology, 2022, 49(4): 243-246.
[6]	Ji Huan, Zhou Juying, Ma Chenying, Xu Xiaoting, Qin Songbing.Progression of radiotherapy for brain metastases in non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(3): 181-184.
[7]	Lin Rongsheng, Wu Chuhai, Guo Yingmei, Wang Tao, Chen Rongbin, Liu Shaoqin, Gan Bing.Efficacy and safety of teriprizumab combined with bevacizumab in the treatment of metastatic MSI-H colorectal cancer above the second line[J]. Journal of International Oncology, 2022, 49(2): 100-105.
[8]	Zhu Yishuo, Cui Yujie, Liu Qi, Li Jun, Fan Yuechao.Analysis of risk factors and prediction model establishment for early postoperative recurrence in glioma patients[J]. Journal of International Oncology, 2022, 49(2): 79-83.
[9]	Kong Chunyu, Sun Pengfei.SLC7A11 and glioma[J]. Journal of International Oncology, 2022, 49(10): 604-607.
[10]	Zhang Hong'e, Zhou Qinghua, Liu Jiewei, Dai Shuang, Zhou Jie.Research progress of brain injuries in patients with small cell lung cancer caused by prophylactic cranial irradiation[J]. Journal of International Oncology, 2021, 48(9): 568-571.
[11]	Guo Shihao, Ren Yeqing, Guo Geng.Molecular mechanism of vasculogenic mimicry in brain glioma[J]. Journal of International Oncology, 2021, 48(6): 362-365.
[12]	Wang Xianwei, Shi Meiyan, Wang Fengqin, Qi Fu, Wang Chaozhe, Zhou Fei.Roles of TSA upregulation miR-4298 targeting inhibition of PADI4 expression in inducing U251 cells apoptosis[J]. Journal of International Oncology, 2021, 48(4): 193-199.
[13]	Han Xiaoyu, He Jun, Wan Chonghua, Luo Jiahong, Bai Gang, Zhang Jianghui, Meng Qiong.Metric evaluation of quality of life instruments for cancer patients-brain neoplasm (QLICP-BN)[J]. Journal of International Oncology, 2021, 48(3): 143-149.
[14]	Sun Yanqi, Ren Yeqing, Guo Geng.Mechanism of inhibitory effect of interferon and its related signal pathway on the invasion of glioma[J]. Journal of International Oncology, 2021, 48(3): 172-175.
[15]	Li Jia, Ma Xiaojie, Wang Yuxiang.Evaluation of the efficacy and safety of adjuvant mFOLFOX6 combined with bevacizumab regimen in the treatment of colorectal cancer liver metastases after radiofrequency ablation[J]. Journal of International Oncology, 2021, 48(12): 729-734.

Bevacizumab for glioma and radiation encephalic necrosis

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments